title: Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
abstract: Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing doxorubicin with epirubicin (Ellence), a less cardiotoxic analog, produced an objective response rate of 84%, but with a low rate of cardiotoxicity. A careful cardiac monitoring in more than 100 patients treated with this combination has demonstrated that the risk of congestive heart failure is below 10% up to a cumulative epirubicin dose of 990 mg/m2. To examine the possibility that the pharmacokinetic and pharmacodynamic interactions that occur when anthracycline and paclitaxel are administered together might result in subadditive antitumor activity, a phase III study is comparing concomitant vs sequential administration of epirubicin and paclitaxel in patients with advanced breast cancer. A phase I/II study of epirubicin plus docetaxel as first-line chemotherapy for advanced breast cancer patients evaluated the maximum tolerated doses and for subsequent studies recommended epirubicin at 75 mg/m2 plus docetaxel at 80 mg/m2. In the adjuvant setting, an ongoing phase III trial is comparing epirubicin plus paclitaxel vs FEC (fluorouracil, epirubicin, and cyclophosphamide [Cytoxan, Neosar]) in node-positive patients. Preliminary data confirm the cardiac safety of these treatments.
authors.affiliation: Divisione di Oncologia Medica, Dipartimento di Oncologia, Ospedale Santa Chiara, Pisa, Italy. pconte@do.med.unipi.it
authors.forename: P
authors.initials: P
authors.lastname: Conte
authors.forename: A
authors.initials: A
authors.lastname: Gennari
authors.forename: V
authors.initials: V
authors.lastname: Guarneri
authors.forename: E
authors.initials: E
authors.lastname: Landucci
authors.forename: S
authors.initials: S
authors.lastname: Donati
authors.forename: B
authors.initials: B
authors.lastname: Salvadori
authors.forename: C
authors.initials: C
authors.lastname: Bengala
authors.forename: C
authors.initials: C
authors.lastname: Orlandini
authors.forename: E
authors.initials: E
authors.lastname: Baldini
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D015251:Epirubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007558:Italy; D015201:Meta-Analysis as Topic; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D043823:Taxoids
chemical_list: D001952:Bridged-Ring Compounds; D043823:Taxoids; D000077143:Docetaxel; C080625:taxane; D015251:Epirubicin; D017239:Paclitaxel